Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI and Alemtuzumab as Conditioning Regimen in Sickle Cell Disease
NCT05384756Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alemtuzumab in sickle cell disease (SCD), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 100 days and Feasibility at 2 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
alemtuzumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05384756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384756.